



Basic Annual Drug List Updates

October 2022

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
ADBRY (tralokinumab-ldrm subcutaneous soln prefilled syr 150 mg/ml)	Brand	Addition, Preferred Status
CLOMID (clomiphene citrate tab 50 mg)	Brand	Addition, Preferred Status
DESCOVY (emtricitabine-tenofovir alafenamide fumarate tab 120-15 mg)	Brand	Addition, Preferred Status
NUCALA (mepolizumab subcutaneous solution pref syringe 40 mg/0.4ml)	Brand	Addition, Preferred Status
OZEMPIC (semaglutide soln pen-inj 2 mg/dose (8 mg/3ml))	Brand	Addition, Preferred Status
QULIPTA (atogepant tab 10 mg)	Brand	Addition, Preferred Status
QULIPTA (atogepant tab 30 mg)	Brand	Addition, Preferred Status
QULIPTA (atogepant tab 60 mg)	Brand	Addition, Preferred Status
VARENICLINE STARTING MONTH BOX (varenicline tartrate tab 0.5 mg x 11 & tab 1 mg x 42 pack)	Brand	Addition, Preferred Status

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Texas (BCBSTX) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.